文献速递角膜与眼表疾病

跨膜蛋白CMTM6减轻实验性干眼眼部炎症反应并改善角膜上皮屏障功能

Transmembrane Protein CMTM6 Alleviates Ocular Inflammatory Response and Improves Corneal Epithelial Barrier Function in Experimental Dry Eye.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2024-01-01

该研究探讨跨膜蛋白CMTM6在干眼病发病中的作用及机制。CMTM6在健康人及小鼠角膜结膜上皮高表达,在干眼病中降低且与疾病严重度相关。Cmtm6敲除干眼小鼠泪液分泌减少、角膜上皮缺损、结膜杯状细胞密度下降、炎症反应上调、屏障破坏及ZO-1表达降低。CMTM6敲低的人角膜上皮细胞在 hyperosmotic stress 下炎症反应增强,CMTM6过表达可减轻;NF-κB p65抑制剂JSH-23可逆转CMTM6敲低细胞的过度炎症反应。CMTM6-NF-κB p65通路可能是干眼病的潜在治疗靶点。

要点

  • CMTM6在健康人及小鼠角膜结膜上皮高表达,在干眼病中降低且与疾病严重度相关。
  • Cmtm6敲除干眼小鼠泪液分泌减少、角膜上皮缺损、结膜杯状细胞密度下降及炎症反应上调。
  • CMTM6敲低人角膜上皮细胞在高渗应激下炎症反应增强,CMTM6过表达可减轻,JSH-23可逆转。

核心结论

  • 眼表CMTM6表达降低参与干眼病发病,CMTM6-NF-κB p65信号通路可能是干眼病有前景的治疗靶点。

研究设计与样本

  • 研究通过数据库分析、RT-PCR、western blot和免疫组化确认CMTM6表达,使用酚红棉线试验测泪液分泌、流式细胞术评估免疫细胞浸润、荧光素钠染色及ZO-1免疫荧光和ECIS评估屏障功能。
  • 采用siRNA和shRNA沉默CMTM6表达,以及慢病毒载体介导CMTM6过表达,通过RT-PCR和CBA分析促炎细胞因子水平。

主要发现

  • CMTM6在健康人和小鼠角膜结膜上皮高表达,在干眼病中显著降低,且该下调与疾病严重度相关。
  • Cmtm6-/-干眼小鼠泪液分泌减少、严重角膜上皮缺损、结膜杯状细胞密度下降及炎症反应上调。
  • Cmtm6-/-干眼小鼠和CMTM6敲低的人角膜上皮细胞系(HCE-T)显示更严重的屏障破坏和ZO-1表达降低。
  • HCE-T细胞中CMTM6敲低增加高渗应激诱导的炎症反应,CMTM6过表达显著减轻该反应。
  • 高渗刺激的HCE-T细胞沉默CMTM6后磷酸化p65水平升高,NF-κB p65抑制剂JSH-23逆转CMTM6敲低细胞高渗诱导的过度炎症反应。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To investigate the impact of transmembrane protein CMTM6 on the pathogenesis of dry eye disease (DED) and elucidate its potential mechanisms. METHODS: CMTM6 expression was confirmed by database analysis, real-time polymerase chain reaction (RT-PCR), western blot, and immunohistochemistry. Tear secretion was measured using the phenol red thread test. Immune cell infiltration was assessed through flow cytometry. Barrier function was evaluated by fluorescein sodium staining, immunofluorescence staining of zonula occludens 1 (ZO-1), and electric cell-substrate impedance sensing (ECIS) assessment. For silencing CMTM6 expression, siRNA and shRNA were employed, along with lentiviral vector-mediated overexpression of CMTM6. Proinflammatory cytokine levels were analyzed by RT-PCR and cytometric bead array (CBA) analysis. RESULTS: CMTM6 showed high expression in healthy human and mouse corneal and conjunctival epithelium but was notably reduced in DED. Notably, this downregulation was correlated with disease severity. Cmtm6-/- dry eye (DE) mice displayed reduced tear secretion, severe corneal epithelial defects, decreased conjunctival goblet cell density, and upregulated inflammatory response. Additionally, Cmtm6-/- DE mice and CMTM6 knockdown human corneal epithelial cell-transformed (HCE-T) cells showed more severe barrier disruption and reduced expression of ZO-1. Knockdown of CMTM6 in HCE-T cells increased inflammatory responses induced by hyperosmotic stress, which was significantly mitigated by CMTM6 overexpression. Moreover, the level of phospho-p65 in hyperosmolarity-stimulated HCE-T cells increased after silencing CMTM6. Nuclear factor kappa B (NF-κB) p65 inhibition (JSH-23) reversed the excessive inflammatory responses caused by hyperosmolarity in CMTM6 knockdown HCE-T cells. CONCLUSIONS: The reduction in CMTM6 expression on the ocular surface contributes to the pathogenesis of DED. The CMTM6-NF-κB p65 signaling pathway may serve as a promising therapeutic target for DED.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Zhou Y, Ma B, Liu Q, et al. Transmembrane Protein CMTM6 Alleviates Ocular Inflammatory Response and Improves Corneal Epithelial Barrier Function in Experimental Dry Eye. Invest Ophthalmol Vis Sci. 2024. PMID: 38165704. doi:10.1167/iovs.65.1.4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。